The enhanced tumor cell invasive potential caused by increased catecholamine release and the subsequent MMP-2 and MMP-9 expression can be successfully abrogated with the pharmacological blockade of MMPs using CMT-3, a broad-spectrum MMP inhibitor, indicating that MMP activity plays an integral role in the pathways of catecholamine-induced increase in tumor cell invasive potential [99]. The gene discussed is MMP2; the disease is neoplasm.